Taysha Gene Therapies Announces Pivotal Trial Design for TSHA-102

Taysha Gene Therapies ( (TSHA) ) just unveiled an update.

On May 28, 2025, Taysha Gene Therapies announced the design details for the pivotal Part B trial of TSHA-102 in Rett syndrome, following positive clinical data from Part A of the REVEAL trials. The trial, supported by the FDA, aims to assess developmental milestone gains in patients aged six and above, with the company planning to initiate the pivotal program in the third quarter of 2025. Additionally, Taysha suspended its ATM Prospectus related to $100 million of common stock but maintained the Sales Agreement in effect.

The most recent analyst rating on (TSHA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Taysha Gene Therapies stock, see the TSHA Stock Forecast page.

Spark’s Take on TSHA Stock

According to Spark, TipRanks’ AI Analyst, TSHA is a Neutral.

The overall stock score reflects a balance between financial challenges and positive technical and earnings call indicators. While financial performance is a significant concern, the stock’s upward momentum and promising clinical developments provide some optimism. The lack of earnings and negative valuation metrics weigh on the score, but the potential for regulatory advancement and improved cash flow stability are key positives.

To see Spark’s full report on TSHA stock, click here.

More about Taysha Gene Therapies

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS).

Average Trading Volume: 2,855,125

Technical Sentiment Signal: Buy

Current Market Cap: $559.2M

For detailed information about TSHA stock, go to TipRanks’ Stock Analysis page.